TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Why Shares in Agios Pharmaceuticals Got Crushed Today

The Motley Fool Logo The Motley Fool By Lee Samaha
Why Shares in Agios Pharmaceuticals Got Crushed Today

Agios Pharmaceuticals' stock dropped nearly 50% after mixed Phase 3 trial results for its sickle cell disease drug mitapavit. The drug met one primary endpoint of hemoglobin response but failed to significantly reduce sickle cell pain crises.

Insights
AGIO   negative

Stock price dropped 50% due to partial failure of clinical trial, missing a key endpoint for sickle cell disease drug despite some positive results